#USA #San Diego #ACROBiosystems #CHO-Direct #ACRO AIx

Revolutionizing Drug Discovery: ACROBiosystems' New Innovations

In a significant step forward within the biotechnology sector, ACROBiosystems has recently introduced an innovative portfolio including ACRO AIx, CHO-Direct, and the GlobalLifeShip supply chain. These new services are specifically designed to enhance the efficiency of drug discovery amid the rapidly growing integration of artificial intelligence (AI).

The Growing Importance of AI in Drug Development

As the use of AI becomes more prevalent in drug discovery, pharmaceutical companies, and research teams are desperately seeking solutions to streamline their processes. The main challenge lies in balancing the rapid generation of candidate molecules through computational methods with the practical validation of these molecules in the lab. For the drug development process to advance, reliable experimental data must be gathered quickly to assess the functionality and potential of these candidates.

ACROBiosystems has recognized this need and aims to bridge the gap between computational predictions and actionable research and development (R&D) decisions. The introduction of CHO-Direct and ACRO AIx seeks to facilitate this transition towards more efficient and effective drug development.

CHO-Direct: Fast-Tracking Antibody Validation

The CHO-Direct service provides an unprecedented four-day turnaround for high-throughput affinity validation of antibodies, from the submission of sequences to the delivery of affinity data. This rapid service is made possible through the use of an optimized Chinese Hamster Ovary (CHO) cell system, which is well-regarded for its ability to maintain key protein-folding and post-translational modification processes. In essence, this creates a seamless digital validation workflow that enables researchers to generate structured data outputs quickly.

Pharmaceutical companies and biotechnology firms can leverage CHO-Direct not only to gain faster access to critical data but also to implement a standardized experimental pathway that verifies computational predictions. Such an approach allows R&D teams to prioritize their resources more effectively, focusing on candidates with the most promise for further investigation.

The capabilities of ACROBiosystems extend well beyond the basic validation process— with support for over 5,000 target proteins and more than 300 challenging membrane protein targets. Additionally, the company is enhancing its TR-FRET kits for functional pathway inhibition screening and is offering a variety of reporter cell lines available for worldwide licensing.

From Rapid Validation to Comprehensive Assessment

Once candidates have undergone rapid validation through CHO-Direct, the next steps can involve assessing cellular functions and higher-order models. Using overexpression techniques, knockout lines, and reporter cell lines, researchers can evaluate various functionalities such as cell binding, internalization, and immune activation. The use of 3D organoid models derived from induced pluripotent stem cells (hiPSCs) provides further biological relevance, enabling early efficacy assessments that can be integral to refining candidate profiles.

ACRO AIx: Comprehensive AI Infrastructure

Complementing the CHO-Direct service, ACRO AIx aims to establish a more extensive wet-lab infrastructure for AI-driven drug discovery. ACRO AIx enhances experimental reproducibility and allows for better data connectivity and workflow management among research teams. By providing standardized products and modular validation capabilities, ACRO AIx ultimately empowers research teams to customize their engagement based on individual laboratory resources and project milestones.

In addition, ACROBiosystems plans to roll out the CHO-Direct Tool Set, which includes dedicated high-expression CHO cell lines, culture media, and reagents for transfection, allowing laboratories to reproduce these systems in-house.

As part of its commitment to connecting products and data, ACRO AIx will offer an AIDD-Ready protein library that equates to real-time access to essential target proteins for drug discovery. Facilitating data-sharing through planned APIs will enable research teams to make informed decisions quickly, thus acknowledging the potential of AI tools to transform R&D workflows.

GlobalLifeShip: A New Era of Supply Chain Management

Recognizing that effective supply chain management is crucial for the global market, ACROBiosystems also unveiled the GlobalLifeShip platform. Designed to enhance cross-border transportation and last-mile delivery, this service will significantly benefit partners looking to penetrate international markets.

By tapping into its established global hubs and leveraging existing supply chains, ACROBiosystems aims to streamline the drug development and validation processes.

Conclusion

With a vision of becoming a cornerstone in the global biopharmaceutical landscape, ACROBiosystems is set to transform how drug discovery is approached in this AI-driven era. By continuously developing robust products and methodologies, the company is not only creating value for the pharmaceutical industry but also working to empower partners in advancing healthcare solutions around the world.